Results 31 to 40 of about 17,995 (248)
Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs. [PDF]
PLoS ONE, 2013 BACKGROUND: Severe polyneuropathy has been observed in a number of patients treated for Parkinson's disease with Levodopa/Carbidopa intestinal gel infusion. This may reflect a rare individual complication or a systematic side effect.
Constanze Jugel +5 more
doaj +1 more source
Mechanisms Involved in Treadmill Walking Improvements in Parkinson's Disease [PDF]
, 2010 [Abstract] Patients with Parkinson's disease (PD) improve gait after treadmill training and while they are walking over the treadmill. However, the mechanisms of these improvements have not been addressed. We designed a treadmill simulator without a belt
Bello, Olalla +3 more
core +2 more sources
Dopaminergic agents: back to the basics – a small review
Journal of Applied Pharmaceutical Research, 2017 Parkinson’s disease is one of the most common neurodegenerative diseases. The motor system is eventually damaged which affects the voluntary movements in a patient. It leads to the death of vital nerve cells in the brain. Women have lesser prevalence due
Neha Sharma +2 more
doaj +1 more source
The Effects of Startle and Non-Startle Auditory Stimuli on Wrist Flexion Movement in Parkinson's Disease [PDF]
, 2013 [Abstract] Startle stimuli lead to shorter reaction times in control subjects and Parkinson's disease (PD) patients. However, non-startle stimuli also enhance movement initiation in PD.
Bello, Olalla +6 more
core +4 more sources
Neurology International, 2020 Parkinson’s disease (PD) is a common neurodegenerative disorder that leads to significant morbidity and disability. PD is caused by a loss of dopaminergic, cholinergic, serotonergic, and noradrenergic neurons in the central nervous system (CNS), and ...
Amnon A. Berger +8 more
doaj +1 more source
Case Reports in Neurology, 2022 Carbidopa-levodopa has been used for more than 50 years in the treatment of Parkinson disease (PD) and other movement disorders. Pyridoxal 5′-phosphate (PLP), an active form of vitamin B6 (pyridoxine), is involved in the decarboxylation of levodopa to ...
Adina Wise +4 more
doaj +1 more source
Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. [PDF]
, 2019 ObjectiveTo understand the safety, putaminal coverage, and enzyme expression of adeno-associated viral vector serotype-2 encoding the complementary DNA for the enzyme, aromatic L-amino acid decarboxylase (VY-AADC01), delivered using novel intraoperative ...
Bankiewicz, Krystof S +10 more
core +1 more source
National surveys : a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease [PDF]
, 2013 BACKGROUND: The purpose of this study was to draw conclusions from patient-reported experiences in two national surveys from Scandinavia with the intention of comparing treatment strategies and increasing our knowledge of factors that affect the ...
Lökk, Johan +3 more
core +1 more source
Current Therapeutic Research, 2020 : Background: Parkinson's disease is a neurodegenerative disorder, and a major cause of disability. Levodopa, a prodrug of dopamine, remains the gold standard in the pharmacological management of Parkinson's disease.
Benedicta Obenewaa Dankyi, MPhil +5 more
doaj +1 more source
Experiment assessment of mass effects in the rat_ implications for small animal PET imaging [PDF]
, 2004 In vivo imaging using positron emission tomography (PET) is important in the development of new radiopharmaceuticals in rodent animal models for use as biochemical probes, diagnostic agents, or in drug development.
Eckelman, William C. +4 more
core +2 more sources